Pharmacy benefit managers occupy a position in the pharmaceutical supply chain for which the public data infrastructure has almost no direct visibility. They negotiate rebates from manufacturers, construct formulary tiers that determine patient access and cost-sharing, and retain a portion of the rebates they secure in transactions that are simultaneously legal, consequential, and largely invisible to any public pricing benchmark. MedPricer’s WAC-ASP spread data traces the downstream effect of PBM contracting—the gap between list price and effective price—without illuminating the mechanism. The gap is visible. The architecture of the gap is not.
Formulary Tier Placement and Its Pricing Consequences
A manufacturer’s formulary tier placement determines, in large part, the volume of patients who access the drug and the cost-sharing burden those patients bear. Preferred tier status—lower patient co-pay, no prior authorization—typically comes at the cost of higher rebates to the PBM. Non-preferred status means lower rebates but also lower volume. Formulary exclusion means no rebates but also essentially no commercially covered volume.
From a manufacturer’s perspective, the decision to pay higher rebates for preferred formulary placement is a volume-versus-margin optimization. For a drug with significant market share to defend, the preferred tier rebate is often a bargain—the alternative is formulary disadvantage and volume erosion that would cost more in lost revenue than the rebate. But the rebate increases gross-to-net, widens the WAC-ASP spread, and signals to external analysts that margin pressure is growing even as the manufacturer’s volume strategy may be working exactly as intended.
The Exclusionary Formulary Dynamic
The Pharmacy Benefits Management industry has moved substantially toward exclusionary formularies—formularies that explicitly exclude certain drugs, rather than simply tiering them unfavorably. ESI, CVS Caremark, and OptumRx each maintain exclusion lists that cover a meaningful number of branded drugs. A drug added to an exclusion list effectively disappears from the commercially covered population’s formulary access, regardless of physician prescribing preferences.
For an analyst tracking WAC and ASP for a drug approaching a formulary exclusion decision, the data signals are difficult to read in advance. The formulary decision itself is confidential. The effective date is known to contracting parties but not to the public. The first observable signal may be in the next quarter’s ASP file—a volume decline reflected in a smaller sales base—rather than in any pricing benchmark.
What Rebate Transparency Proposals Would Change
The debate over rebate transparency has moved through several legislative cycles without producing a federal disclosure requirement for PBM rebate amounts. The Trump administration’s abortive ‘rebate rule,’ which would have required rebates to be passed through to patients at the point of sale, was withdrawn before implementation. The Biden-era IRA included provisions addressing insulin price caps and Part D redesign but left the core structure of commercial PBM rebate opacity intact.
If a mandatory rebate disclosure regime were enacted, the informational value of WAC-ASP spread analysis would diminish significantly—the mechanism would become directly observable rather than inferred. That is worth stating clearly: MedPricer’s cross-dataset inference approach is most valuable in a market structure defined by opacity. Greater transparency would reduce the inference premium while potentially creating different analytical opportunities. For now, the opacity is structural and durable.
Reading PBM Power Through Benchmark Divergence
One underappreciated use of MedPricer’s data is as a measure of PBM negotiating leverage over time. If the three largest PBMs have genuinely increased their bargaining power over manufacturers in a given therapeutic category, the evidence should appear in widening WAC-ASP spreads for the leading branded drugs in that category. That spread widening reflects the higher rebates being extracted through formulary negotiations—which is precisely the mechanism through which PBM leverage expresses itself in pricing data.
This reading is imprecise—other mechanisms also widen the spread—but as a directional signal of PBM power concentration, it has analytical merit. Trend data across therapeutic categories and across time offers a rough topology of where PBM leverage is strongest, where it is stable, and where manufacturers have successfully resisted formulary pressure. That topology is not available from any single benchmark dataset. It requires the cross-dataset architecture that MedPricer is building.
